- Home
- EXEL vs KNSL Comparison
EXEL vs KNSL Comparison
Compare EXEL & KNSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- KNSL
- Stock Information
- Founded
- EXEL 1994
- KNSL 2009
- Country
- EXEL United States
- KNSL United States
- Employees
- EXEL N/A
- KNSL N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- KNSL Property-Casualty Insurers
- Sector
- EXEL Health Care
- KNSL Finance
- Exchange
- EXEL Nasdaq
- KNSL Nasdaq
- Market Cap
- EXEL 9.8B
- KNSL 10.9B
- IPO Year
- EXEL 2000
- KNSL 2016
- Fundamental
- Price
- EXEL $36.17
- KNSL $453.87
- Analyst Decision
- EXEL Buy
- KNSL Buy
- Analyst Count
- EXEL 18
- KNSL 9
- Target Price
- EXEL $37.59
- KNSL $479.57
- AVG Volume (30 Days)
- EXEL 2.2M
- KNSL 204.0K
- Earning Date
- EXEL 05-13-2025
- KNSL 04-24-2025
- Dividend Yield
- EXEL N/A
- KNSL 0.15%
- EPS Growth
- EXEL 170.77
- KNSL 15.35
- EPS
- EXEL 1.76
- KNSL 17.37
- Revenue
- EXEL $2,168,701,000.00
- KNSL $1,638,131,000.00
- Revenue This Year
- EXEL $5.78
- KNSL $16.22
- Revenue Next Year
- EXEL $10.94
- KNSL $14.80
- P/E Ratio
- EXEL $20.64
- KNSL $26.17
- Revenue Growth
- EXEL 18.50
- KNSL 22.79
- 52 Week Low
- EXEL $20.14
- KNSL $366.92
- 52 Week High
- EXEL $40.26
- KNSL $531.79
- Technical
- Relative Strength Index (RSI)
- EXEL 43.89
- KNSL 47.90
- Support Level
- EXEL $34.90
- KNSL $420.52
- Resistance Level
- EXEL $40.26
- KNSL $466.98
- Average True Range (ATR)
- EXEL 1.21
- KNSL 15.02
- MACD
- EXEL -0.19
- KNSL 0.03
- Stochastic Oscillator
- EXEL 23.69
- KNSL 47.83
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About KNSL Kinsale Capital Group Inc.
Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, a professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.